Pomerantz LLP is investigating Karyopharm Therapeutics for possible securities fraud related to a recent announcement of large cash retention awards for top executives. Following the disclosure of retention bonuses ranging from $625,000 to $1.725 million, Karyopharm's stock price fell by over 21%. The investigation will determine if the company or its officers engaged in unlawful business practices. Investors affected by the stock drop may join a class action lawsuit as the case develops.
American Eagle Outfitters reported strong Q2 results with earnings per share of $0.79, far exceeding the $0.22 estimate, and revenue of $1.38 billion, slightly above expectations. The growth was driven by a 25% revenue increase from its Aerie and OFF...
AeroVironment reported a strong quarterly earnings per share (EPS) of $0.59, well above analyst expectations of $0.22, showing solid profitability. However, its revenue of $329.06 million fell short of the estimated $451.95 million, reflecting mixed ...
At the Barclays 19th Annual Global Consumer Staples Conference, Dine Brands executives discussed their portfolio, which includes 1,550 Applebee's units, 1,800 IHOP units, and 100 Fuzzy's Taco units. The company emphasized the strong consumer appeal o...
Shopify has acquired Tailwind Labs, known for its popular Tailwind CSS framework used by major platforms like ChatGPT and Reddit. The Tailwind team will now focus on helping Shopify merchants design custom storefronts, manage sales and inventory, and...
Insilico Medicine has dosed the first patient in a Phase III clinical trial for Rentosertib, an AI-discovered drug targeting idiopathic pulmonary fibrosis (IPF). The trial, conducted at multiple centers in China, aims to evaluate the drug's efficacy ...
